Trials / Completed
CompletedNCT01470144
Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epoprostenol | Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2015-06-01
- Completion
- 2015-07-01
- First posted
- 2011-11-11
- Last updated
- 2025-02-04
- Results posted
- 2016-12-09
Source: ClinicalTrials.gov record NCT01470144. Inclusion in this directory is not an endorsement.